{
    "eid": "2-s2.0-85142751937",
    "title": "Basis to Aid Crisis: Favipiravir Oral Solution for Hospital Compounding During COVID-19 Drug Shortage",
    "cover-date": "2023-02-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Pharmaceutical Science",
            "@code": "3003",
            "@abbrev": "PHAR"
        }
    ],
    "keywords": [
        "COVID-19",
        "Favipiravir",
        "Formulation development",
        "Hospital compounding",
        "Oral solution",
        "Specification",
        "Stability"
    ],
    "authors": [
        "Bodin Tuesuwan",
        "Wunlapa Mueannoom",
        "Promporn Jamnongtanachot",
        "Ariya Khunvichai",
        "Chiravi Pavitrapok",
        "Kawinthida Wongpakdee",
        "Supasil Sra-ium",
        "Nithi Mahanonda",
        "Vorasit Vongsutilers"
    ],
    "citedby-count": 0,
    "ref-count": 21,
    "ref-list": [
        "Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase",
        "Avigan Tablets 200 mg",
        "Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea",
        "Clinical and virological characteristics of ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone, 2014",
        "AVIFAVIR for treatment of patients with moderate coronavirus disease 2019 (COVID-19): interim results of a phase II/III multicenter randomized clinical trial",
        "Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis",
        "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial",
        "Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients",
        "Association of early favipiravir use with reduced COVID-19 fatality among hospitalized patients",
        "Guidelines for Clinical Practice, Diagnosis, Treatment and Prevention of Healthcare-Associated Infection in Response to Patients with COVID-19 Infection",
        "The international council for harmonisation of technical requirements for pharmaceuticals for human Use (ICH)",
        "The United State Pharmacopeia. \u3008791\u3009 pH",
        "The United State Pharmacopeia. \u300861\u3009 Microbiological examination of nonsterile products: microbial enumeration tests",
        "The International Council for harmonisation of technical requirements for pharmaceuticals for human use (ICH)",
        "Japanese Pharmaceuticals and Medical Devices Agency",
        "Pharmacokinetic comparison of favipiravir oral solution and tablet formulations in healthy Thai Volunteers",
        "IMWP Monographs on Favipiravir and on Favipiravir Tablets",
        "The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)",
        "The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)",
        "<1111>Microbiological examination of nonsterile products: acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use",
        "Favipiravir (SARS-CoV-2) degradation impurities: Identification and route of degradation mechanism in the finished solid dosage form using LC/LC\u2013MS method"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022464",
            "affilname": "Chulabhorn Royal Academy",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022464",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "127008786",
            "affilname": "Ltd.",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/127008786",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Chulabhorn Hospital",
        "Medica Innova Co. Ltd",
        "Medica Innova Co., Ltd.",
        "Chulabhorn Royal Academy",
        "Chulalongkorn University"
    ]
}